Compass Debt To Equity from 2010 to 2025

CMPX Stock  USD 2.61  0.01  0.38%   
Compass Therapeutics Debt To Equity yearly trend continues to be fairly stable with very little volatility. Debt To Equity is likely to outpace its year average in 2025. Debt To Equity is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. View All Fundamentals
 
Debt To Equity  
First Reported
2010-12-31
Previous Quarter
0.0105
Current Value
0.011
Quarterly Volatility
0.12256684
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Compass Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Compass Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 9.5 M or Interest Income of 9.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.26. Compass financial statements analysis is a perfect complement when working with Compass Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Compass Therapeutics Correlation against competitors.
For more information on how to buy Compass Stock please use our How to Invest in Compass Therapeutics guide.

Latest Compass Therapeutics' Debt To Equity Growth Pattern

Below is the plot of the Debt To Equity of Compass Therapeutics over the last few years. It is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. Compass Therapeutics' Debt To Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Compass Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.03 %10 Years Trend
Slightly volatile
   Debt To Equity   
       Timeline  

Compass Debt To Equity Regression Statistics

Arithmetic Mean(0.09)
Geometric Mean0.08
Coefficient Of Variation(142.14)
Mean Deviation0.10
Median(0.17)
Standard Deviation0.12
Sample Variance0.02
Range0.4077
R-Value0.72
Mean Square Error0.01
R-Squared0.51
Significance0
Slope0.02
Total Sum of Squares0.23

Compass Debt To Equity History

2025 0.011
2024 0.0105
2023 0.0117
2022 0.0162
2021 0.0288
2020 0.23
2019 -0.13

About Compass Therapeutics Financial Statements

Compass Therapeutics investors use historical fundamental indicators, such as Compass Therapeutics' Debt To Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Compass Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Debt To Equity 0.01  0.01 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Compass Stock Analysis

When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.